Artemether PCD Pharma Franchise Company

Cafoli Lifecare is a WHO-GMP certified pharmaceutical company offering a Artemether PCD pharma franchise across India. Our portfolio spans 6 Artemether formulations in Dry Syrup, Injection and Tablet forms, backed by consistent quality and monopoly-based distribution rights for our franchise partners.

What is Artemether?

Artemether is a fast-acting artemisinin-derived antimalarial that generates reactive free radicals inside the malaria parasite, rapidly reducing parasite load. It is most often used as part of artemisinin-based combination therapy (ACT), typically with lumefantrine, to clear infection and limit resistance. Its profile is documented on PubChem.

Therapeutic Applications

Artemether formulations treat uncomplicated and severe Plasmodium falciparum malaria; the intramuscular injection is used for severe and cerebral malaria, while dry syrups and tablets serve uncomplicated cases in children and adults. It is prescribed by general physicians, paediatricians and hospital clinicians, especially in endemic regions.

Why Artemether is a High-Potential Molecule for Distributors

Malaria remains endemic across large parts of India, and artemether-based ACT is the WHO-recommended first-line treatment, making it a government-programme and prescription staple with strong seasonal (monsoon) demand. The availability of paediatric syrup, adult tablet and emergency injection forms lets a distributor cover both retail and institutional channels. Regions with high malaria burden offer defensible, geography-driven monopoly opportunities.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers district and state-wise monopoly rights, WHO-GMP certified and DCGI-approved manufacturing, attractive promotional inputs, and the backing of a network of 1000+ franchise partners. Our transparent supply and billing model helps you build a profitable, protected business in your territory.

References

1. PubChem — Artemether
2. MedlinePlus — Malaria
3. PubMed — Artemether literature